Bach J F
Immunology Department, Hôpital Necker, Paris, France.
J Autoimmun. 1992 Apr;5 Suppl A:3-10. doi: 10.1016/0896-8411(92)90014-h.
Immunosuppressive agents have proved to be remarkably successful in controlling the course of a growing number of autoimmune diseases. The usual occurrence of relapses when the treatment is stopped and the persisting risk of long term complications linked to over-immunosuppression have prompt the search for new approaches, aiming at more rapid and selective intervention and earlier onset of therapy. New chemicals and monoclonal antibodies presently represent the main clinical orientations, while at the experimental level major efforts are directed towards peptide therapy (autoantigen, T cell receptor) and tolerance induction.
免疫抑制剂已被证明在控制越来越多的自身免疫性疾病病程方面非常成功。治疗停止后通常会复发，以及与免疫抑制过度相关的长期并发症的持续风险，促使人们寻找新的方法，旨在实现更快速、更有选择性的干预和更早开始治疗。新的化学物质和单克隆抗体目前代表了主要的临床方向，而在实验层面，主要努力方向是肽疗法（自身抗原、T细胞受体）和诱导耐受。
